StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Eli Lilly's (LLY) Earnings Outlook Continues to Look Favorable VS Peers, Reiterate Overweight - Cantor Fitzgerald
February 3, 2022 7:13 AM
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $335.00 price target on Eli Lilly (NYSE: LLY), following the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Trader Talk
Next Articles
Eli Lilly (LLY) PT Lowered to $305 at BMO Capital
February 4, 2022 6:55 AM
Eli Lilly's (LLY) Fundamentals and Pipeline are Encouraging, Continue to Support Positive View - BMO Capital Markets
February 3, 2022 7:22 AM
Eli Lilly pushes back timeline for Alzheimer's drug application
February 3, 2022 6:35 AM
Eli Lilly & Co. (LLY) Tops Q4 EPS by 34c, Revenue Beats, Offers Guidance
February 3, 2022 6:26 AM
Eli Lilly & Co. (LLY) February weekly 250 straddle priced for a move of +/- 3.5% into quarter results
February 3, 2022 4:54 AM
